CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab

Am J Hematol. 2000 Oct;65(2):171-3. doi: 10.1002/1096-8652(200010)65:2<171::aid-ajh14>3.0.co;2-z.

Abstract

B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / blood*
  • Child
  • Female
  • Herpesvirus 4, Human / genetics
  • Humans
  • Infant
  • Intestine, Small / transplantation
  • Liver Transplantation / adverse effects
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / etiology
  • Lymphoma, Large B-Cell, Diffuse / virology
  • Lymphoproliferative Disorders / drug therapy
  • Lymphoproliferative Disorders / etiology*
  • Lymphoproliferative Disorders / virology
  • Male
  • Middle Aged
  • Organ Transplantation / adverse effects*
  • Postoperative Complications / drug therapy
  • Postoperative Complications / etiology
  • RNA, Messenger / blood
  • Rituximab
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • RNA, Messenger
  • Rituximab